Yoshinaga Takuma, Niou Tatsuyuki, Niihara Toru, Kajiya Yoriko, Hori Emiko, Tomiyoshi Ayako, Tokudome Erena, Nishimata Hiroto, Takei Takayuki, Yoshida Masahiro
Division of Clinical Application, Nanpuh Hospital, Kagoshima, Japan.
Gastroenterology, Nanpuh Hospital, Kagoshima, Japan.
J Cancer. 2018 Nov 25;9(24):4736-4741. doi: 10.7150/jca.25404. eCollection 2018.
Pancreatic cancer is one of the tumors with the worst prognosis, with the 5-year survival rate reported to be 6%. The number of patients suffering from pancreatic cancer in recent years has continued to increase dramatically. Carbohydrate antigen 19-9 is an established biomarker of pancreatic cancer, but it does not have sufficient ability to detect pancreatic cancer at an early stage. We focused on angiopoietin-like protein 2 (ANGPTL2), which has been reported to be related to chronic inflammation and Type 2 diabetes mellitus. In this study, whether ANGPTL2 can detect early pancreatic cancer was evaluated. It was found that the concentration of serum ANGPTL2 was significantly higher in pancreatic cancer patients and tumor stage 0-I patients than in healthy individuals (5.84 ± 1.82 ng/mL vs 3.61 ± 0.64 ng/mL; < 0.001) (5.68 ± 0.79 ng/mL vs 3.61 ± 0.64 ng/mL; = 0.010). In addition, the diagnostic capability of serum ANGPTL2 levels for pancreatic cancer was evaluated using receiver operating characteristic (ROC) curve analysis. The area under the ROC curve (AUC) for ANGPTL2 was 0.906 (95% confidence interval (CI): 0.815-0.997; < 0.001). To identify the risk factors for pancreatic cancer, multivariate regression models were used. Ten factors were included, and increasing age (odds ratio (OR), 1.318, 95% CI, 1.058-1.642; = 0.014) and high ANGPTL2 levels (OR, 22.219, 95% CI, 1.962-251.659, = 0.012) were found to be independent risk factors for pancreatic cancer, with ANGPTL2 having the strongest relationship. In addition, serum ANGPTL2 levels were strongly correlated with inflammatory markers, with blood sugar levels showing the strongest correlation with serum ANGPTL2 levels. In conclusion, this study suggested that an elevated serum ANGPTL2 level has the potential to be a biomarker capable of early detection of pancreatic cancer, and it was correlated with inflammation of the pancreas and the risk of developing diabetes mellitus.
胰腺癌是预后最差的肿瘤之一,据报道其5年生存率为6%。近年来,胰腺癌患者的数量持续急剧增加。糖类抗原19-9是一种公认的胰腺癌生物标志物,但它在早期检测胰腺癌方面能力不足。我们关注到血管生成素样蛋白2(ANGPTL2),据报道它与慢性炎症和2型糖尿病有关。在本研究中,评估了ANGPTL2是否能够检测早期胰腺癌。研究发现,胰腺癌患者以及0-I期肿瘤患者血清ANGPTL2浓度显著高于健康个体(5.84±1.82 ng/mL对3.61±0.64 ng/mL;<0.001)(5.68±0.79 ng/mL对3.61±0.64 ng/mL;=0.010)。此外,使用受试者工作特征(ROC)曲线分析评估了血清ANGPTL2水平对胰腺癌的诊断能力。ANGPTL2的ROC曲线下面积(AUC)为0.906(95%置信区间(CI):0.815-0.997;<0.001)。为了确定胰腺癌的危险因素,使用了多变量回归模型。纳入了10个因素,发现年龄增加(比值比(OR),1.318,95%CI,1.058-1.642;=0.014)和ANGPTL2水平升高(OR,22.219,95%CI,1.962-251.659,=0.012)是胰腺癌的独立危险因素,其中ANGPTL2的关系最为密切。此外,血清ANGPTL2水平与炎症标志物密切相关,血糖水平与血清ANGPTL2水平的相关性最强。总之,本研究表明血清ANGPTL2水平升高有可能成为一种能够早期检测胰腺癌的生物标志物,并且它与胰腺炎症和患糖尿病的风险相关。